The management of patients anticoagulated with warfarin and referred for coronary angiography presents a substantial challenge to the physician who must balance the risks of periprocedural hemorrhage with thromboembolism. The aim of this study was to evaluate the feasibility and safety of diagnostic coronary angiography and percutaneous coronary intewention (PCI) during uninterrupted watfarin therapy.
Methods:
Patients treated with wadarin were prospectively identified and enrolled in the study. Coronary angiography was performed in the usual fashion using a femoral approach without interrupting warfarin. PCI was performed as clinically indicated.
Results:
Nineteen diagnostic cardiac catheterizations and 6 percutaneous coronary interventions were performed in 23 patients. The mean age was 72 (+/-9) years and 12 (52%) were male. The primary indication for anticoagulation was atria1 fibrillation in 11 (46%), mechanical valve in 5 (22%). deep venous thrombosis in 5 (22%) and stroke in 2 (9%). The mean international normalized ratio (INR) was 2.4 (+/-0.5, range 1.6-3.5). The primaty indication for catheterization was acute coronary syndrome in 16 (64%). elective coronary evaluation in 4 (16%), valvular heart disease in 2 (8%), congestive heart failure in 2 (6%) and atrial septal defect in 1 (4%). Seventeen (68%) procedures were performed during inpatient hospitalization. Venous sheaths were used in 10 (44%) procedures. 
Conclusions:
To our knowledge, this study is the first to demonstrate that PCI in patients with thrombocytopenia on presentation can be pelformed relatively safely as there is no difference in reinfarction, stroke, and death compared to patients with normal platelet counts. An increased bleeding risk was manifested in groin hematomas and an increased need for transfusion. This suggests that, although PCI is safe, caution should be used in these patients.
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Hydration Versus N-Acetylcysteine for Protection of Renal Function in Patients With Renal Insufficiency Undergoing Percutaneous Coronary Intervention
Anne S. Kanderian. Raed H. Abdelhadi, Deepak L. Bhatt, Jakob Schneider, Mina K.
Chung, The Cleveland Clinic Foundation, Cleveland, OH Background:
Patients with renal insufficiency are at higher risk for renal worsening aHer percutaneous coronary intervention (PCI). The efficacy of N-acetylcysteine (NAC) in preventing renal failure in patients undergoing PCI is controversial.
Methods:
From a clinical and research database of PCI (Jan 2OOOJuly 2002) and chalt reviews, patients with renal insufficiency (creatinine~l.2mg/dl and/or estimated creatinine clearance<60ml/min) were identified. Nonionic contrast dye was employed during PCI. Changes in serum creatinine concentration 24-26 hours after PCI were compared in those patients who received NAC and hydration, hydration alone, and in those who received neither. Data were analyzed using Student's t-tests.
Results: Of 65 patients with renal insufficiency and who had baseline and follow up creatinine levels, NAC and hydration were used in 26 (mean creatinine prior to PCI 2.4Ql.5 mgldl compared to 3.4122.73 mgldl in those who did not receive NAC,p=O.O9). 26 of patients received hydration alone, and 29 had neither NAC nor hydration. The mean creatinine decreased by 0.06$39 mgidl in patients who received NAC and hydration compared to an increase of 0.5&l .36 mg/dl in patients who did not receive either,p=0.031.
In patients who received hydration alone, the mean creatinine decreased by 0.13$0.40 mg/dl,p=0.015.
However, there was no statistical significance in patients who received NAC and hydration compared to those who only received hydration.p=0.46.
Conclusion:
In patients with chronic renal insufficiency undergoing PCI, the use of NAC along with hydration, and hydration alone were both associated with a significant protection of renal function. There was no statistical significance in protection of renal function in patients who had NAC and hydration compared to hydration alone. A prospective randomization of NAC in addition to hydration is warranted to determine whether there is additional benefit of NAC in PCI. Backgrounct Deterioration of renal function is a major concern in predisposed patients undergoing coronary angiography. Gadolinium is a contrast agent, used routinely for magnetic resonance imaging. It is safe and has shown no nephrotoxicity.
However, significant limitations in image quality are encountered when this drug is used alone, even at the maximum recommended dose. The aim of this prospective pilot study was to evaluate the efficacy and the safety of Gadolinium enhanced with low-dose non-ionic contrast agent for coronary angiography in patients with impaired renal function. Methods: We performed coronary angiography in 15 patients at high-risk for renal failure by mixing gadolinium with a small quantity of non-ionic contrast agent.Results:
The mean volume of Gadolinium used per patient was 44 mL (0.6 + 0.2 mUkg of body weight) and the mean volume of non-ionic contrast agent was 22 mL (0.322 0.2 mUkg of body weight 
